A detailed history of Wells Fargo & Company transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 23,019 shares of CRDF stock, worth $86,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,019
Previous 7,825 194.17%
Holding current value
$86,091
Previous $41,000 24.39%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.22 - $5.89 $33,730 - $89,492
15,194 Added 194.17%
23,019 $51,000
Q1 2024

May 10, 2024

BUY
$1.46 - $5.91 $7 - $29
5 Added 0.06%
7,825 $41,000
Q4 2023

Feb 09, 2024

BUY
$0.96 - $1.55 $16 - $26
17 Added 0.22%
7,820 $11,000
Q3 2023

Nov 13, 2023

BUY
$1.38 - $2.18 $5 - $8
4 Added 0.05%
7,803 $10,000
Q2 2023

Aug 15, 2023

BUY
$1.37 - $1.95 $16 - $23
12 Added 0.15%
7,799 $11,000
Q1 2023

May 12, 2023

BUY
$1.45 - $2.09 $8,850 - $12,757
6,104 Added 362.69%
7,787 $12,000
Q4 2022

Feb 13, 2023

BUY
$1.22 - $1.66 $18 - $24
15 Added 0.9%
1,683 $2,000
Q3 2022

Nov 14, 2022

SELL
$1.54 - $3.21 $33 - $70
-22 Reduced 1.3%
1,668 $2,000
Q2 2022

Aug 12, 2022

SELL
$1.17 - $2.61 $8,915 - $19,888
-7,620 Reduced 81.85%
1,690 $4,000
Q1 2022

May 16, 2022

SELL
$2.11 - $7.25 $24,980 - $85,832
-11,839 Reduced 55.98%
9,310 $23,000
Q4 2021

Feb 14, 2022

BUY
$5.18 - $7.24 $94,115 - $131,543
18,169 Added 609.7%
21,149 $127,000
Q3 2021

Nov 15, 2021

BUY
$5.01 - $7.58 $10,345 - $15,652
2,065 Added 225.68%
2,980 $20,000
Q2 2021

Aug 16, 2021

SELL
$6.65 - $10.04 $33,602 - $50,732
-5,053 Reduced 84.67%
915 $6,000
Q1 2021

May 13, 2021

SELL
$9.1 - $19.57 $328,983 - $707,494
-36,152 Reduced 85.83%
5,968 $56,000
Q4 2020

Feb 09, 2021

BUY
$12.02 - $24.71 $500,068 - $1.03 Million
41,603 Added 8047.0%
42,120 $757,000
Q3 2020

Nov 05, 2020

BUY
$4.25 - $14.19 $1,904 - $6,357
448 Added 649.28%
517 $8,000
Q2 2020

Aug 13, 2020

BUY
$0.78 - $5.1 $53 - $351
69 New
69 $0

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $162M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.